KCT0003545招募中未知
Combination chomotherapy of nanoxel and herzuma in patients with relapsed or metastatic salivary gland carcinoma : open label single arm multicenter phase II study
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 41
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •?Histologically-confirmed HER2 positive (immunohistochemistry [IHC] 3+, and/or fluorescence in situ hybridization[FISH] positive with = two-fold amplification) salivary duct carcinoma(SDC), and other salivary gland carcinomas which are similar to SDC in histopathological findings, including adenocarcinoma, not otherwise specified, acinic cell carcinoma, squamous cell carcinoma, anaplastic carcinoma, high grade mucoepidermoid carcinoma, and carcinoma ex pleomorphic adenoma (Except for Adenoid cystic carcinoma)
- •? locally advanced, unresectable, relapse or metastatic cancer
- •? Allow treatment of all previous orders
- •? age = 20 years
- •? ECOG performance status 0-1
- •? At least one measurable tumor lesion according to RECIST 1.1
- •? Expected survival for approximately 12 weeks or longerExpected survival for approximately 12 weeks or longer
- •? At least 4 weeks later after surgery or at least 2 weeks after radiotherapy
- •? Organ function as evidence by the following;,
- •ANC = 1,500 cells/mm3,
- •Hemoglobin = 10 g/dL (transfusion allowed),
- •Platelet count = 100,000 /mm3;
- •Total bilirubin = 1.5 × ULN, AST/ALT = 2.5 × ULN, (if liver metastases(+): AST, ALT =5.0 x ULN);
- •Creatinine clearance = 50 mL/min or serum creatinine = 1.5 x UNL
- •? Echocardiography showed normal LVEF =55%)
- •? Written informed consent
排除标准
- •? Those who have received Her-2 treatment (ex: Herceptin etc.)
- •? Severe or unstable cardiac disease, including (for example) coronary artery disease requiring increased doses of anti-anginal medication and/or coronary angioplasty (including stent placement) within the preceding 24 months(congestive heart failure NYHA III or IV, unstable angina pectoris, history of myocardial infarction within the last twelve months, significant arrhythmias)
- •? Uncontrolled systemic illness such as DM, hypertension, hypothyroidism and infection, infectious fever
- •? Patients with active hepatitis B, active hepatitis C, HIV
- •? Pregnant and nursing women (Women of childbearing age should agree to use effective contraceptive methods from the first day of the study drug infusion to 7 months after the last dose of the study drug infusion, and agree to check for pregnancy test(result: negative)).
- •? Male patients, those who did not consent to not donate sperm from the first day of the study drug infusion to 90 days after the last dose of study drug infusion
- •? Within the past 5 years, a malignant tumor of the other site (except treated basal cell carcinoma of the skin or carcinoma in situ of the cervix.)
- •? Patients with meningiomas, active metastatic lesions under the brain or subdural (Exceptions are made when completing topical treatment (radiotherapy, stereotactic surgery) and using stable doses of anticonvulsants and steroids before starting clinical trial treatment).
- •? Patients who were treated with anticancer treatments, radiotherapy, chemotherapy, clinical trial medication within 2 weeks before starting clinical trial
- •? Toxicity above CTCAE grade 2, not resolved from previous chemotherapy (Except: hair loss, vitiligo)
- •? Patient with history of rodent-derived protein, trastuzumab or hypersensitivity to the components of trastuzumab
- •? Patient with severe respiratory distress due to progressive malignant tumors or who need oxygen supplementation
- •? Patient with severe bone marrow suppression
- •? Patient with Nanoxel and components of Nanoxel, severe hypersensitivity reactions to polysorbate 80
- •? Patient with history of exposure to the following anthracycline cumulative doses
- •- Doxorubicin > 500mg/m2
- •- Liposomal doxorubicin > 500mg/m2
- •- Epirubicin > 720mg/m2
- •- Mitoxantrone > 120mg/m2
- •- Idarubicin > 90mg/m2
- •(If another anthracycline or two or more anthracyclines are used, the cumulative dose should not exceed 500mg/m2 doxorubicin equivalent capacity.)
研究者
相似试验
Unknown
2 期
Combination of Nanoxel and Herzuma in Salivary Duct CarcinomaSalivary Duct CarcinomaNCT03614364Samsung Medical Center41
已完成
不适用
Combination therapy with a molecular target drug and iron chelator for the treatment of intractable hepatocellular carcinomaadvanced hepatocellular carcinomaJPRN-UMIN000013461Department of Gastroenterology, Okayama University Hospital10
已完成
1 期
A phase 1 study of combination chemotherapy for hepatocellular carcinoma using Miripla® (SM11355) and IA-call® (DDP-H)Hepatocellular carcinomaJPRN-UMIN000003541iigata Hepatocellular Carcinoma Therapy Study Group18
进行中（未招募）
1 期
Concurrent helical tomotherapy with chemotherapy in unresectable stage III non-small cell lung cancer (NSCLC):a phase I/II trial of radiation dose escalation and fixed dose chemotherapy. - TomoCTstage III locally advanced non small cell lung cancer (LA-NSCLC)MedDRA version: 8.1Level: LLTClassification code 10029519Term: Non-small cell lung cancer stage IIIEUCTR2006-003708-21-BEAZ-VUB30
进行中（未招募）
1 期
Effectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir/ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infectioEUCTR2020-001605-23-ESBasque Health Service108